Metoject 20 mg/0.4 ml is a pre-filled injection used to treat rheumatoid arthritis, psoriasis, and psoriatic arthritis, especially in cases where other treatments have failed to control psoriasis. It contains 20 mg of methotrexate in a ready-to-use injectable form.
Each pre-filled Metoject syringe contains the active ingredient methotrexate, which inhibits several enzymes, helping to reduce inflammation and prevent cell division.
Metoject injections are used in the treatment of:
Active rheumatoid arthritis in adults.
Severe, treatment-resistant psoriasis that interferes with daily life and does not respond to other treatments such as phototherapy or retinoids.
Severe psoriatic arthritis in adults.
Methotrexate injections are administered subcutaneously once a week.
The medication must be used under medical supervision.
The doctor will determine the appropriate dose based on the patient’s condition.
It typically takes 4 to 8 weeks for the therapeutic effect to appear.
Overdosing can be fatal; the prescribed dosage must be strictly followed.
Not suitable for children under 3 years of age.
Methotrexate may cause the following side effects:
Mouth inflammation
Indigestion
Loss of appetite
Abdominal pain
Abnormal liver function test results
Mouth ulcers
Diarrhea
Skin rash and itching
Skin redness
Headache
Fatigue
Dizziness
Decreased blood cell count
Metoject should not be used in the following cases:
Hypersensitivity to its components
Severe kidney or liver disease
Blood disorders
Regular consumption of large amounts of alcohol
Serious infections (e.g., tuberculosis, HIV, or any immune-compromising diseases)
Mouth, stomach, or intestinal ulcers
Pregnancy and breastfeeding
Receiving live vaccines concurrently with treatment
Consult your doctor before using methotrexate injections for rheumatoid arthritis, especially if you:
Are elderly or feel weak and fatigued
Have liver problems
Are dehydrated
Avoid skin or mucous membrane contact with the medication; in case of accidental exposure, wash the affected area with water immediately.
Metoject is not recommended during pregnancy as it may cause miscarriage or severe fetal abnormalities. Pregnancy should be avoided during treatment and for up to six months after stopping the medication.
Breastfeeding should be discontinued before and during treatment with Metoject.
Metoject (methotrexate) may temporarily affect sperm production in men and egg production in women, but these effects are generally reversible.
Consult a doctor or pharmacist before using Metoject alongside other medications, including:
Antibiotics
Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen
Probenecid
Diuretics
Other rheumatoid arthritis medications like sulfasalazine
Mercaptopurine
Retinoids (used for psoriasis and skin disorders)
Diabetes medications
Medications for stomach ulcers or acid reflux, such as omeprazole
Keep out of reach of children
Store below 25°C
Do not use after the expiration date